Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norethisterone enanthate (NET-EN) is a long-acting, injectable progestogen-only contraceptive. It is a prodrug of norethisterone, a synthetic second-generation progestin. When administered intramuscularly, typically at a dose of 200 mg every 8 weeks, it provides highly effective contraception by inhibiting ovulation, increasing the viscosity of cervical mucus to prevent sperm penetration, and altering the endometrium to discourage implantation. It is also frequently used in combination formulations, such as with estradiol valerate (e.g., Mesigyna or Compound Norethisterone Enanthate), for monthly administration. NET-EN is widely utilized globally for long-term birth control and is recognized for its high efficacy and reversible nature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norethisterone enanthate.